Cell Signaling Technology

Product Pathways - Jak/Stat Pathway

IL-1RA (20D8) Mouse mAb #3865

Applications Reactivity Sensitivity MW (kDa) Isotype
W H Endogenous 18 Mouse IgG1

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

IL-1RA (20D8) Mouse mAb detects endogenous IL-1RA protein. It does not cross-react with other related proteins.

Source / Purification

Monoclonal antibody is produced by immunizing animals with recombinant human IL-1RA protein.

Western Blotting

Western Blotting

Western blot analysis of variable amounts of recombinant human IL-1RA protein and A431 cell lysate using IL-1RA (20D8) Mouse mAb.

Background

The founding members of the interleukin-1 (IL-1) superfamily include pro-inflammatory cytokines IL-1α and IL-1β, and a third protein that acts as an IL-1 receptor antagonist (IL-1RA). At least six similar proteins have been recently identified, including a homolog of IL-1RA (IL1F5). The three better-characterized proteins (IL-1a, IL-1b and IL-1RA) are mainly expressed in macrophages, monocytes, and dendritic cells. IL-1a and IL-1b act as potent inflammatory cytokines that help regulate host defense and immune responses (1). Binding of these pro-inflammatory cytokines to an IL-1 receptor recruits adapter proteins (such as IRAK) to the receptor. Phosphorylation of these adaptor proteins promotes downstream signaling cascades associated with the immune response (2). Altered expression of both IL-1a and IL-1b is associated with an extensive list of human disorders, including Alzheimer's disease, rheumatoid arthritis, psoriasis and various forms of cancer (3,4). IL-1RA acts as an anti-inflammatory cytokine, binding the IL-1 receptor to limit the response to inflammation (5). Because it plays a key role in regulating the inflammatory response, recombinant IL-1RA is a therapeutic agent used in the treatment of diseases such as rheumatoid arthritis. Alternatively, mutation of the corresponding IL-1RA gene may be associated with susceptibility to the development of specific cancers (6).

  1. Pelegrin, P. (2008) Drug News Perspect 21, 424-33.
  2. Ringwood, L. and Li, L. (2008) Cytokine 42, 1-7.
  3. Griffin, W.S. and Mrak, R.E. (2002) J Leukoc Biol 72, 233-8.
  4. Kamangar, F. et al. (2006) Cancer Epidemiol Biomarkers Prev 15, 1920-8.
  5. Arend, W.P. Cytokine Growth Factor Rev 13, 323-40.
  6. Sehouli, J. et al. Anticancer Res 22, 3421-4.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products